Mankind Pharma Ltd

Mankind Pharma Ltd has announced an improved ESG Rating of 64, placing it in the 'Strong' category, up from a previous rating of 57 ('Adequate'). The company's Core ESG Rating also saw an increase to 71 from 60. CRISIL ESG Ratings & Analytics independently assigned this rating based on FY2026 disclosures and publicly available information, without direct engagement from the company. This positive development highlights the company's enhanced environmental, social, and governance performance.

Mankind Pharma Limited has entered into an exclusive in-licensing and marketing agreement with China-based Chongqing Chenan Biopharmaceutical Co., Ltd. for the commercialization of Insulin Degludec and Insulin Degludec + Aspart Combination in India. This partnership aims to strengthen Mankind Pharma's presence in the diabetes segment and expand its injectable diabetes portfolio. The agreement aligns with Mankind Pharma's strategy of leveraging global innovation through strategic partnerships and in-licensing opportunities, particularly from China's growing biopharmaceutical sector. The company plans to enhance patient access to advanced diabetes therapies in India.

Mankind Pharma Ltd has completed the realignment of security cover for its Non-Convertible Debentures (NCDs). Following requisite approvals, revised security has been created over tangible and intangible assets. Consequently, the pledge on 28,280 equity shares of Bharat Serums and Vaccines Limited (BSVL), representing 38.68% of its paid-up equity, has been released. The revised security cover is 1.26 times the outstanding NCD amount, and no BSVL shares are now under pledge for NCDs.

Mankind Pharma Ltd has announced the incorporation of its wholly owned subsidiary in the Netherlands, named "Mankind Pharma (Netherlands) B.V.". This incorporation follows an earlier intimation dated July 11, 2026, and is in compliance with SEBI Listing Regulations. The company has confirmed that all necessary disclosures as required by the SEBI Master Circular dated January 30, 2026, were already provided in the previous intimation. This strategic move is expected to facilitate the company's international expansion and operations.

Mankind Pharma Ltd has announced the appointment of Mr. Anish Vanraj Bafna as an Additional Director, designated as a Non-Executive Independent Director. The appointment was approved by the Board of Directors at a meeting held on August 10, 2026, based on the recommendation of the Nomination and Remuneration Committee. Mr. Bafna's appointment is for a term of 5 consecutive years, subject to member approval via postal ballot. He brings over 30 years of experience in the healthcare and medical devices sector, including significant leadership roles at Healthium Medtech Limited and Baxter International. Mr. Bafna is not related to any existing directors or promoters and meets the independence criteria.

Mankind Pharma Ltd announced the appointment of Mr. Anish Vanraj Bafna as an Additional Director, designated as a Non-Executive Independent Director. The appointment, effective August 10, 2026, was approved by the Board of Directors based on the recommendation of the Nomination and Remuneration Committee. Mr. Bafna's appointment is for a term of 5 years, subject to shareholder approval via postal ballot. He brings over 30 years of experience in the healthcare and medical devices sector, including leadership roles at Healthium Medtech Limited and Baxter International. Mr. Bafna is not related to any existing directors or promoters and meets the independence criteria.

Mankind Pharma Ltd announced the appointment of Mr. Anish Vanraj Bafna as an Additional Director, designated as a Non-Executive Independent Director, effective August 10, 2026. This appointment is subject to member approval via postal ballot. Mr. Bafna brings over 30 years of experience in the healthcare and medical devices sector, including significant leadership roles at Healthium Medtech Limited and Baxter International. He is not related to any existing directors or key management personnel and meets independence criteria. The board meeting where this was approved commenced at 3:30 p.m. IST and concluded at 3:45 p.m. IST.

Mankind Pharma announced its financial results for the first quarter ended June 30, 2026, reporting a robust 12.9% year-on-year revenue growth to ₹4,031 Crore. EBITDA saw a significant increase of 24.7% to ₹1,060 Crore, with EBITDA margins improving by 250 basis points to 26.3%. Profit After Tax (PAT) grew by 29.1% to ₹574 Crore, and PAT margin expanded by 170 basis points to 14.2%. The company's domestic business, excluding Consumer Healthcare, grew by 11.0%, driven by strong performance in chronic therapies and specialty segments. The international business also showed strong momentum, with revenue up 29.0%. Diluted EPS increased by 29.6% to ₹13.7.

Mankind Pharma Ltd's Board of Directors, in a meeting held on July 30, 2026, approved the issuance of a corporate guarantee in favor of its wholly-owned subsidiary, Bharat Serums & Vaccines Limited (BSV). The board also considered and approved the unaudited standalone and consolidated financial results for the quarter ended June 30, 2026. The financial results were accompanied by a Limited Review Report from joint statutory auditors S. R. Batliboi & Co. LLP and Bhagi Bhardwaj Gaur & Co. Further disclosures regarding the corporate guarantee were provided as per SEBI regulations, along with a certificate from the auditors.

Mankind Pharma Ltd announced its unaudited financial results for the quarter ended June 30, 2026. The Board of Directors approved the standalone and consolidated financial results. The company also approved the issuance of a corporate guarantee in favor of its wholly-owned subsidiary, Bharat Serums and Vaccines Limited (BSV). The financial results were accompanied by a Limited Review Report from joint statutory auditors M/s. S. R. Batliboi & Co. LLP and M/s. Bhagi Bhardwaj Gaur & Co. A certificate from the joint statutory auditors under Regulation 54 of the Listing Regulations for the quarter ended June 30, 2026, was also enclosed.